Trial Profile

Phase 1b Dose Expansion Study of NXC-201 for the Treatment of Patients with Relapsed or Refractory AL Amyloidosis

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NXC 201 (Primary) ; Cyclophosphamide; Fludarabine
Indications Amyloid light-chain amyloidosis
Focus Adverse reactions; Therapeutic Use
Acronyms NEXICART-2
Sponsors Nexcella

Most Recent Events

03 Jun 2025 According to an Immix Biopharma, Inc media release, data from this study were presented at an oral presentation of interim results at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois.
03 Jun 2025 Interim results presented in an Immix Biopharma Media Release.
03 Jun 2025 Primary endpoint (Complete response rate) has been met, according to an Immix Biopharma, Inc media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com